American Renal Associates (PRIVATE.ARA)

Overall impact
B (63)

Commentary

American Renal Associates is a strong overall performer. With a 'B' rating of 63.2 for overall impact (69th percentile compared to all companies), American Renal Associates ranks 49th out of 76 industry peers, behind IMAC, Enzo Biochem, Invitae and 45 others, and ahead of Ortho Clinical Diagnostics, Charles River Laboratories, Psychemedics and 24 others. On top material causes for American Renal Associates's industry (Healthcare Software & Services), American Renal Associates
Impact
Cause PRIVATE.ARA
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
4,932
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Massachusetts, United States
Share classes
PRIVATE.ARA
Description
American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States focused exclusively on joint venture partnerships with physicians. The company, through its subsidiaries, owns and operates kidney dialysis facilities for patients suffering from chronic kidney failure or end-stage renal disease (ESRD). As of March 31, 2016, it owned and operated 194 dialysis clinics in 25 states and the District of Columbia. The company was formerly known as C.P. Atlas Holdings, Inc. and changed its name to American Renal Associates Holdings, Inc. in February 2011. American Renal Associates Holdings, Inc. was founded in 1999 and is headquartered in Beverly, Massachusetts.
Material causes
Ethos considers the following causes material for American Renal Associates, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.